The prognosis for delayed immune recovery in HIV-infected children might be associated with pre-cART CD4+ T cell count irrespective of co-infection with tuberculosis
- PMID: 39773670
- PMCID: PMC11707843
- DOI: 10.1186/s13104-024-07032-y
The prognosis for delayed immune recovery in HIV-infected children might be associated with pre-cART CD4+ T cell count irrespective of co-infection with tuberculosis
Abstract
Background: Immune reconstitution following the initiation of combination antiretroviral therapy (cART) significantly impacts the prognosis of individuals infected with human immunodeficiency virus (HIV). Our previous studies have indicated that the baseline CD4+ T cells count and percentage before cART initiation are predictors of immune recovery in TB-negative children infected with HIV, with TB co-infection potentially causing a delay in immune recovery. However, it remains unclear whether these predictors consistently impact immune reconstitution during long-term intensive cART treatment in TB-negative/positive children infected with HIV.
Results: We confirmed that the baseline CD4+ T cell count is a significant predictor of immune recovery following long-term intensive cART treatment among children aged 0 to 13 years. Children with lower CD4+ T cell count prior cART initiation did not show substantial immunological recovery during the follow-up period. Interestingly, children who were co-infected with TB and had higher baseline CD4+ T cell count eventually achieved good immunological recovery comparable to the TB-negative HIV-infected children. Hence, the baseline CD4+ T cell count at the onset of treatment serves as a reliable predictor of immunological reconstitution in HIV-infected children with or without TB co-infection. Taken together, this follow-up study validates our previous findings and further establishes that initiating cART early alongside early HIV testing can help prevent the diminished CD4+ T cell count associated with inadequate immunological reconstitution.
Keywords: CART initiation; CD4+ T cell count; HIV; Immune recovery; Piecewise linear and mixed-effects models; TB.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The study was conducted in accordance with the ethical standards of the institutional and/or national research committee and the Declaration of Helsinki. Informed consent to participate was obtained from the participants and the study protocol received approval from the Yale University Human Investigation Committee and the University of Ghana Medical School. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Figures



Update of
-
The Prognosis for Delayed Immune Recovery in HIV-Infected Children might be Associated with Pre-cART CD4 + T cell Count Irrespective of Co-Infection with Tuberculosis.Res Sq [Preprint]. 2024 Apr 19:rs.3.rs-4243586. doi: 10.21203/rs.3.rs-4243586/v1. Res Sq. 2024. Update in: BMC Res Notes. 2025 Jan 7;18(1):6. doi: 10.1186/s13104-024-07032-y. PMID: 38699317 Free PMC article. Updated. Preprint.
Similar articles
-
The Prognosis for Delayed Immune Recovery in HIV-Infected Children might be Associated with Pre-cART CD4 + T cell Count Irrespective of Co-Infection with Tuberculosis.Res Sq [Preprint]. 2024 Apr 19:rs.3.rs-4243586. doi: 10.21203/rs.3.rs-4243586/v1. Res Sq. 2024. Update in: BMC Res Notes. 2025 Jan 7;18(1):6. doi: 10.1186/s13104-024-07032-y. PMID: 38699317 Free PMC article. Updated. Preprint.
-
Pre-HAART CD4+ T-lymphocytes as biomarkers of post-HAART immune recovery in HIV-infected children with or without TB co-infection.BMC Infect Dis. 2020 Oct 15;20(1):756. doi: 10.1186/s12879-020-05458-w. BMC Infect Dis. 2020. PMID: 33059622 Free PMC article.
-
Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy.BMC Infect Dis. 2017 Jul 25;17(1):517. doi: 10.1186/s12879-017-2627-y. BMC Infect Dis. 2017. PMID: 28743248 Free PMC article.
-
Association of CD4 T cell count and optimal timing of antiretroviral therapy initiation with immune reconstitution inflammatory syndrome and all-cause mortality for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis.Int J Clin Exp Pathol. 2021 Jun 15;14(6):670-679. eCollection 2021. Int J Clin Exp Pathol. 2021. PMID: 34239668 Free PMC article. Review.
-
Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis.Curr Opin HIV AIDS. 2012 May;7(3):268-75. doi: 10.1097/COH.0b013e3283524e32. Curr Opin HIV AIDS. 2012. PMID: 22495739 Review.
References
-
- Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA. 2005;293:2767–75. 10.1001/jama.293.22.2767. - PubMed
-
- Lawn SD, et al. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis. 2010;10:489–98. 10.1016/s1473-3099(10)70078-5. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials